Close Menu

NEW YORK – Twist Bioscience said on Thursday that it has priced a $100 million public stock offering at $33 per share.

The firm is offering approximately 3 million share of common stock. JP Morgan, Cowen and Company, and Evercore Group are acting as joint book-running managers and Robert W. Baird is acting as lead manager. Twist will grant the underwriters an option to purchase up to an additional 454,545 shares at the public offering price, less the underwriting discount and commissions.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers have developed a robotic lab assistant, the Verge reports.

CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.

The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.

In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.